-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Dolby Laboratories, Inc. Just Beat EPS By 17%: Here's What Analysts Think Will Happen Next
Dolby Laboratories, Inc. Just Beat EPS By 17%: Here's What Analysts Think Will Happen Next
The quarterly results for Dolby Laboratories, Inc. (NYSE:DLB) were released last week, making it a good time to revisit its performance. It looks like a credible result overall - although revenues of US$290m were in line with what the analysts predicted, Dolby Laboratories surprised by delivering a statutory profit of US$0.39 per share, a notable 17% above expectations. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.
Check out our latest analysis for Dolby Laboratories
NYSE:DLB Earnings and Revenue Growth August 12th 2022Following the latest results, Dolby Laboratories' four analysts are now forecasting revenues of US$1.37b in 2023. This would be a notable 9.0% improvement in sales compared to the last 12 months. Statutory earnings per share are predicted to surge 24% to US$2.47. Before this earnings report, the analysts had been forecasting revenues of US$1.42b and earnings per share (EPS) of US$2.88 in 2023. The analysts seem less optimistic after the recent results, reducing their sales forecasts and making a real cut to earnings per share numbers.
The consensus price target fell 14% to US$100.00, with the weaker earnings outlook clearly leading valuation estimates. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. The most optimistic Dolby Laboratories analyst has a price target of US$128 per share, while the most pessimistic values it at US$90.00. As you can see, analysts are not all in agreement on the stock's future, but the range of estimates is still reasonably narrow, which could suggest that the outcome is not totally unpredictable.
Of course, another way to look at these forecasts is to place them into context against the industry itself. It's clear from the latest estimates that Dolby Laboratories' rate of growth is expected to accelerate meaningfully, with the forecast 7.2% annualised revenue growth to the end of 2023 noticeably faster than its historical growth of 3.8% p.a. over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 13% per year. It seems obvious that, while the future growth outlook is brighter than the recent past, Dolby Laboratories is expected to grow slower than the wider industry.
The Bottom Line
The most important thing to take away is that the analysts downgraded their earnings per share estimates, showing that there has been a clear decline in sentiment following these results. On the negative side, they also downgraded their revenue estimates, and forecasts imply revenues will perform worse than the wider industry. The consensus price target fell measurably, with the analysts seemingly not reassured by the latest results, leading to a lower estimate of Dolby Laboratories' future valuation.
Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. At Simply Wall St, we have a full range of analyst estimates for Dolby Laboratories going out to 2024, and you can see them free on our platform here..
You should always think about risks though. Case in point, we've spotted 2 warning signs for Dolby Laboratories you should be aware of.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
年的季度业绩杜比实验室公司(纽约证券交易所股票代码:DLB)上周发布,这使得现在是重新审视其业绩的好时机。总体而言,这看起来是一个可信的结果-尽管2.9亿美元的收入与分析师的预测一致,但杜比实验室出人意料地实现了每股0.39美元的法定利润,比预期高出17%。对于投资者来说,这是一个重要的时刻,因为他们可以在公司的报告中跟踪公司的表现,查看专家对明年的预测,以及对业务的预期是否有任何变化。因此,我们收集了最新的盈利后预测,看看估计数字对明年的影响。
查看我们对杜比实验室的最新分析
纽约证券交易所:DLB收益和收入增长2022年8月12日根据最新的业绩,杜比实验室的四名分析师现在预测2023年的收入为13.7亿美元。与过去12个月相比,这将是销售额显著提高9.0%。预计每股法定收益将飙升24%,至2.47美元。在这份收益报告之前,分析师一直预测2023年收入为14.2亿美元,每股收益(EPS)为2.88美元。在最近的财报公布后,分析师们似乎不那么乐观了,他们下调了销售预期,并大幅下调了每股收益数据。
普遍预期股价下跌14%,至100.00美元,较弱的盈利前景明显领先于估值预期。不过,还有另一种方式来考虑价格目标,那就是看看分析师提出的价格目标的范围,因为广泛的估计可能表明,对企业可能出现的结果有不同的看法。最乐观的杜比实验室分析师的目标价为每股128美元,而最悲观的分析师则认为目标价为90美元。正如你所看到的,分析师对该股的未来并不完全一致,但估计范围仍然相当窄,这可能表明结果并不是完全不可预测的。
当然,看待这些预测的另一种方式是将它们放在与行业本身相反的背景下。从最新的估计中可以清楚地看到,杜比实验室的增长率预计将大幅加快,截至2023年底的预测年化收入增长率为7.2%,明显快于其历史上3.8%的年增长率。在过去的五年里。相比之下,我们的数据显示,类似行业的其他公司(有分析师覆盖)的收入预计将以每年13%的速度增长。很明显,尽管未来的增长前景比最近的过去更光明,但杜比实验室的增长速度预计将慢于整个行业。
底线
最重要的是,分析师们下调了他们的每股收益预期,表明业绩公布后,市场人气明显下降。不利的一面是,他们还下调了营收预期,预测意味着营收表现将逊于整个行业。一致的目标价大幅下降,分析师们似乎对最新的结果并不放心,导致对杜比实验室未来估值的估计较低。
根据这一思路,我们认为,业务的长期前景比明年的收益更相关。在Simply Wall St.,我们有一系列分析师对杜比实验室到2024年的预测,你可以在我们的平台上免费看到。
不过,你应该始终考虑风险。举个例子,我们发现杜比实验室的2个警告标志你应该意识到。
对这篇文章有什么反馈吗?担心内容吗? 保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
本文由Simply Wall St.撰写,具有概括性。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。Simply Wall St.对上述任何一只股票都没有持仓。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧